<DOC>
	<DOCNO>NCT00316030</DOCNO>
	<brief_summary>Bexarotene may useful treatment Acute Myeloid Leukemia ( AML ) . This first study use bexarotene treat patient AML . The main purpose study establish proper dose bexarotene use treat AML . The side effect profile bexarotene patient AML also explore .</brief_summary>
	<brief_title>Study Bexarotene Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>Despite recent advance cancer treatment , prognosis still poor patient relapse chemotherapy resistant AML . Further aggressive chemotherapy attempt , generally yield poor result . This clinical study first use bexarotene treatment patient relapse chemotherapy resistant AML . The main purpose study identify maximum safe dose bexarotene patient AML . Another objective study explore side effect profile bexarotene AML patient . The study organize initial patient get low dose bexarotene take daily . If patient tolerate drug , later patient get high daily dos . Further group patient continue increase dose bexarotene maximum tolerate dose identify . The stu dy end point . Patients take drug daily mouth time AML worsen experience unacceptable side effect . Their participating end point .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>Age &gt; 18 year . Must histologically confirm diagnosis nonM3 AML proven bone marrow biopsy . Patients CML myeloid blast crisis eligible . Willing able give inform consent . Must receive prior induction therapy conventional chemotherapy and/or Mylotarg otherwise eligible conventional chemotherapy ECOG performance status 02 Must recover toxicity prior chemotherapy . Women childbearing potential must use effective contraception enrollment study negative pregnancy test within 1 week study enrollment . They must continue use effective contraception 3 month stop bexarotene . Men must agree use effective method contraception take bexarotene 3 month stop therapy . History pancreatitis . Active alcohol abuse Taken bexarotene past . WBC &gt; 10,000/uL time enrollment . Patients may take hydrea WBC control time enrollment . Cytotoxic chemotherapy Mylotarg within past 7 day hydrea . Significant organ dysfunction : total bilirubin &gt; 3x ULN , AST ALT &gt; 3x ULN , creatinine &gt; 4mg/dL , blood pressure support medication mechanical ventilation . Serious medical psychiatric condition may compromise safety patient participate study . Women childbearing potential pregnant actively breast feed . Active participant investigational treatment study AML . Unable/unwilling perform require followup . Life expectancy le 1 month . Use blood growth factor ( GCSF , GMCSF , Aranesp , erythropoietin , Neumega ) within 1 week prior treatment initiation . Uncontrolled hyperlipidemia ( triglyceride &gt; 1000 treatment triglyceride lower medication ) . History myeloablative allogeneic stem cell transplant . Known history HIV . Uncontrolled active infection Known active CNS involvement AML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Bexarotene</keyword>
	<keyword>Leukemia</keyword>
</DOC>